Canaccord Genuity Lifts Aclaris Therapeutics Target to $13 From $10
Canaccord Genuity raised its price target on Aclaris Therapeutics to $13 from $10 and kept its Buy rating, according to Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Canaccord Genuity increased its price target on Aclaris Therapeutics (ACRS) to $13 a share from $10. The firm kept its Buy rating on the stock.
Dow Jones Newswires reported the move, citing Benzinga's ratings listing for the company.
why it matters
Analyst target changes like this are routine and reflect one firm's updated valuation of a single company. They carry limited weight for the broader market.
tags
instruments
sources
- Aclaris Therapeutics Price Target Raised to $13.00/Share From $10.00 by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:37 UTC
- DexCom Price Target Raised to $97.00/Share From $90.00 by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:44 UTC
- Biohaven Price Target Raised to $32.00/Share From $21.00 by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:40 UTC
- Viking Therapeutics Price Target Raised to $118.00/Share From $106.00 by Canaccord Genuity — Dow Jones Newswires, 31 October 2026 at 00:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗